These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

657 related items for PubMed ID: 18768247

  • 1. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis.
    Del Casar JM, Martín A, García C, Corte MD, Alvarez A, Junquera S, González LO, Bongera M, García-Muñiz JL, Allende MT, Vizoso F.
    Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):147-52. PubMed ID: 18768247
    [Abstract] [Full Text] [Related]

  • 2. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.
    Clin Cancer Res; 2007 Apr 15; 13(8):2329-34. PubMed ID: 17438091
    [Abstract] [Full Text] [Related]

  • 3. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM, Zhang BN, Xuan LX, Zhao P.
    Zhonghua Zhong Liu Za Zhi; 2009 Jun 15; 31(6):447-51. PubMed ID: 19950556
    [Abstract] [Full Text] [Related]

  • 4. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G.
    Hum Pathol; 2006 Sep 15; 37(9):1217-26. PubMed ID: 16938528
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
    Kusińska R, Potemski P, Jesionek-Kupnicka D, Kordek R.
    Pol J Pathol; 2005 Sep 15; 56(3):107-10. PubMed ID: 16334976
    [Abstract] [Full Text] [Related]

  • 6. Identification of a basal-like subtype of breast ductal carcinoma in situ.
    Livasy CA, Perou CM, Karaca G, Cowan DW, Maia D, Jackson S, Tse CK, Nyante S, Millikan RC.
    Hum Pathol; 2007 Feb 15; 38(2):197-204. PubMed ID: 17234468
    [Abstract] [Full Text] [Related]

  • 7. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
    Cancer; 2008 Mar 01; 112(5):995-1000. PubMed ID: 18098228
    [Abstract] [Full Text] [Related]

  • 8. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
    Lee JA, Kim KI, Bae JW, Jung YH, An H, Lee ES, Korean Breast Cancer Society.
    Breast Cancer Res Treat; 2010 Aug 01; 123(1):177-87. PubMed ID: 20574671
    [Abstract] [Full Text] [Related]

  • 9. Clinical significance of basal-like subtype in triple-negative breast cancer.
    Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H.
    Breast Cancer; 2009 Aug 01; 16(4):260-7. PubMed ID: 19701681
    [Abstract] [Full Text] [Related]

  • 10. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P, Christodoulou C, Kalogeras KT, Eleftheraki AG, Bobos M, Batistatou A, Valavanis C, Tzaida O, Timotheadou E, Kronenwett R, Wirtz RM, Kostopoulos I, Televantou D, Koutselini E, Papaspirou I, Papadimitriou CA, Pectasides D, Gogas H, Aravantinos G, Pavlidis N, Arapantoni P, Skarlos DV, Fountzilas G.
    Cancer Chemother Pharmacol; 2012 Feb 01; 69(2):533-46. PubMed ID: 21901395
    [Abstract] [Full Text] [Related]

  • 11. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
    Iwase H, Kurebayashi J, Tsuda H, Ohta T, Kurosumi M, Miyamoto K, Yamamoto Y, Iwase T.
    Breast Cancer; 2010 Apr 01; 17(2):118-24. PubMed ID: 19466512
    [Abstract] [Full Text] [Related]

  • 12. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
    Shibuta K, Ueo H, Furusawa H, Komaki K, Rai Y, Sagara Y, Kamada Y, Tamaki N.
    Breast Cancer; 2011 Oct 01; 18(4):292-8. PubMed ID: 20571962
    [Abstract] [Full Text] [Related]

  • 13. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA, Bauer KR, Brown MM, Caggiano V.
    Breast J; 2009 Oct 01; 15(6):593-602. PubMed ID: 19764994
    [Abstract] [Full Text] [Related]

  • 14. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F.
    Hum Pathol; 2008 Feb 01; 39(2):167-74. PubMed ID: 18045647
    [Abstract] [Full Text] [Related]

  • 15. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [Abstract] [Full Text] [Related]

  • 16. Application of a new classification to a breast tumor series from a population-based cancer registry: demographic, clinical, and prognostic features of incident cases, Palermo Province, 2002-2004 .
    Zarcone M, Amodio R, Campisi I, Cusimano R, Dolcemascolo C, Miceli V, Traina A, Macaluso M.
    Ann N Y Acad Sci; 2009 Feb 01; 1155():222-6. PubMed ID: 19250207
    [Abstract] [Full Text] [Related]

  • 17. Distribution of molecular breast cancer subtypes among Tunisian women and correlation with histopathological parameters: a study of 194 patients.
    Ben Abdelkrim S, Trabelsi A, Missaoui N, Beizig N, Bdioui A, Anjorin A, Jomaa W, Mokni M.
    Pathol Res Pract; 2010 Nov 15; 206(11):772-5. PubMed ID: 20850937
    [Abstract] [Full Text] [Related]

  • 18. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
    Wang Y, Yin Q, Yu Q, Zhang J, Liu Z, Wang S, Lv S, Niu Y.
    Breast Cancer Res Treat; 2011 Nov 15; 130(2):489-98. PubMed ID: 21837481
    [Abstract] [Full Text] [Related]

  • 19. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
    Staaf J, Ringnér M, Vallon-Christersson J, Jönsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, Luts L, Grabau D, Fernö M, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A.
    J Clin Oncol; 2010 Apr 10; 28(11):1813-20. PubMed ID: 20231686
    [Abstract] [Full Text] [Related]

  • 20. Is triple negative a prognostic factor in breast cancer?
    Nishimura R, Arima N.
    Breast Cancer; 2008 Apr 10; 15(4):303-8. PubMed ID: 18369692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.